

COPD as a **COVID-19** risk group Is genetic background the reason?




Marçalo, R.^{1, 2}, Neto, S.¹, Pinheiro, M.¹, Rodrigues, A.J.³, Sousa, N.³, Santos, M.A.S.¹, Simão, P.⁴, Valente, C.⁵, Andrade, L.⁵, Marques, A.², and Moura, G.R.¹ ruifilipemarcalo@ua.pt

¹Genome Medicine laboratory, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro (Portugal); ²Lab 3R - Respiratory Research and Rehabilitation Laboratory, School of Health Sciences (ESSUA) & iBiMED, University of Aveiro, Aveiro (Portugal); ³Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga (Portugal); ⁴Pulmonology Department, Unidade Local de Saúde de Matosinhos, Porto (Portugal); ⁵Pulmonology Department, Centro Hospitalar do Baixo Vouga, Aveiro (Portugal);

Background

Results

- Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis upon COVID-19 infection¹.
- No differences in genetic risk for COVID-19 susceptibility or severity were found between people with COPD and the control group (all p-values > 0.01) (figure 1);
- High populational variability observed in COVID-19 related outcomes².



Aim


• To explore the genetic background as a possible answer to COVID-19 infection response heterogeneity, either for the poor prognosis in people with COPD or across healthy worldwide populations.

• All populations showed significant differences from the European population in genetic risk for COVID-19 susceptibility and severity (all p-values < 0.0001) (figure 2).

Table 1. Sociodemographic, anthropometric and clinical characteristics of participants.

Characteristics	Baixo Vouga cohort		Portuguese cohort	
	COPD (n=255)	Control (n=243)	Baixo Vouga (only control) + Minho (n=623)	
Age (years)	68 [61, 74]	67 [60, 72]	66 [58 <i>,</i> 72]	
Gender (Male), n (%)	203 (79.61%)	176 (72.43%)	359 (57.62%)	
Body mass Index (Kg/m ²)	25.97 [23.44, 29.73]	27.32 [24.91, 29.75]	27.53 [25.08, 30.22]	
FEV ₁ (Litres)	1.32 [0.94, 1.81]	2.58 [2.11, 3.06]	n.d.	
FEV ₁ /FVC	53.02 [41.24 <i>,</i> 61.94]	83.90 [78.01, 89.02]	n.d.	


N (%) - number of individuals and corresponding percentage; remaining data is presented as medians with interquartile range in square brackets. FEV1 - Forced Expiratory Volume in 1-sec in litres; FVC - Forced Vital Capacity in litres; n.d. - no data available.



Methods

- 1. Identification of genetic variants associated with COVID-19 susceptibility (rs286914 and rs12329760) and severity (rs657152 and rs11385942)³⁻⁵.
- 2. Assessment of effect allele frequencies
 - 1. COPD cohort and control group;
 - 2. Worldwide populations (Spanish, Italian, European, African, American and Asian).
- 3. Computation of bi-allelic and polygenic (our cohort only) risk scores.
- 4. Comparison of effect allele frequencies/proportions of cumulative number of risk alleles – Chi-Square test.
- 5. Polygenic risk scores comparisons between COPD and control groups student's t

Figure 1. A and B: Allele frequencies for significant SNPs; C and D: Number of people with a cumulative number of risk alleles; E and F: P olygenic risk assessment. Top panel (A/ C/E): genetic risk for COVID-19 susceptibility; bottom panel (B/D/F): genetic risk for severe COVID -19. 0 to 4: sum of effect alleles for each COVID-19 outcome.





6. Statistical significance was set at 0.01.

Figure 2. Estimation on the number of people with a cumulative number of risk alleles in the world major populations for A - susceptibilit y for COVID-19 infection (rs286914 + rs12329760) and B – severe COVID-19 with respiratory failure (rs657152 + rs11385942). 0 to 4 repre sent the sum of effect alleles for each COVID-19 associated phenotype. ***: p-value<0.0001. Statistical analyses were performed using t he European population as reference.

Conclusions

• Low genetic contribution for COVID-19 infection predisposition or worse outcomes in people with COPD.

• High genetic heterogeneity across worldwide populations for the same alleles, even within European subpopulations.

References: 1Attaway, A., et al. (2020). "SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: An analysis of Cleveland clinic's COVID-19 registry" EclinicalMedicine 26:100515; ²Stawicki, S. et al. (2020). "The 2019-2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint American college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper". J Global Infect Dis 12(2): 47–93. ³Kachuri, L. et al. (2020). "The landscape of host genetic factors involved in infection to common viruses and SARS-CoV-2". Genome Medicine 12,93; ⁴Hou, Y. et al. (2020). "New insights into genetic susceptibility of COVID-19: An ACE2 and TMPRSS2 polymorphism analysis". BMC Med. 18, 216; ⁵ Ellinghaus, D. et al. (2020). "Genomewide Association Study of Severe Covid-19 with Respiratory Failure". N. Engl. J. Med. 383:1522-

Acknowledgements: This work was funded by FEDER (Fundo Europeu de Desenvolvimento Regional) funds through COMPETE 2020, Operational Programme for Competitiveness and Internationalization (POCI) (POCI-01-0145-FEDER-028806;POCI-01-0145-FEDER-016428), CENTRO 2020 (CENTRO-46-2016-02) and by Fundação para a Ciência e a Tecnologia (FCT) (PTDC/DTP-PIC/2284/2014;PTDC/SAU-SER/28806/2017;PTDC/BIA-MIC/31849/2017). The iBiMED is supported by FCT funds under 1200 Marcaller UIDP/04501/2020. C[®]MPETE





1534.